defendil

Defendil is a medication used to treat symptoms of Parkinson's disease, a progressive neurological disorder that affects movement. It belongs to a class of drugs known as monoamine oxidase B inhibitors (MAO-B inhibitors). Defendil works by increasing the levels of dopamine, a neurotransmitter that is depleted in Parkinson's disease, thereby improving motor symptoms such as tremors, rigidity, and bradykinesia (slowness of movement).

Defendil is typically prescribed as an adjunct to levodopa, another common medication for Parkinson's disease. It is often used in patients who experience fluctuations in their levodopa therapy, such as "on-off" phenomena, where symptoms come and go. Defendil can help to stabilize dopamine levels and reduce these fluctuations.

The medication is available in tablet form and is usually taken once or twice daily. Common side effects include nausea, dizziness, and fatigue. Serious side effects are rare but can include serotonin syndrome, a potentially life-threatening condition that occurs when serotonin levels in the body become too high.

Defendil was first approved for medical use in the United States in 2003. It is marketed under the brand name Rasagiline. The drug is generally well-tolerated and has been shown to be effective in improving the quality of life for many Parkinson's disease patients. However, individual responses to the medication can vary, and it is important for patients to work closely with their healthcare providers to manage their condition effectively.